cost of glp-1 agonists Antagonists Increase Plan Drug Spend - What's Next A Heavy Price: The Economic

Industry developments include AbbVies USD2.23 billion deal with Gubra A/S to develop an amylin-targeting obesity drug, and Eli Lillys strategic price reduction for its weight-loss drug Zepbound to maintain market share

issued a statement from Soumi Saha, senior vice president for government affairs, saying the company is gratified to see CMS crack down on plans ability to retroactively deny approved hospital stays. MA appeals rights are being strengthened through provisions clarifying that coverage determinations are subject to notification requirements and subsequent appeal if they take place during concurrent review of inpatient admissions

Discussion GLP-1RA fills increased rapidly between 2018 and 2023

Diabetes Care 45 , 27532786 (2022) I

In the pancreas, these medications stimulate glucose-dependent insulin secretion, meaning they promote insulin release only when blood glucose levels are elevated